Amin, who was previously chief scientific officer at Smith & Nephew PLC (LON:SN) and senior vice president of business development Biogen Inc (NASDAQ:BIIB), will also be a member of the remuneration committee.
READ: Arix Bioscience notes portfolio company Iterum releases topline results for a Phase 3 trial of antibiotic
Amin is currently chief executive at GMP-Orphan and venture partner at Advent Life Sciences, following a 25-year career in the life sciences industry.
Arix NED Franz Humer is retiring from the board at the same time.
“We are very pleased to have Naseem join the board,” Jonathan Peacock, chairman at Arix, said in a release.
“His broad experience in life sciences, corporate development and venture capital, coupled with his strong industry network, will be invaluable in guiding Arix’s vision of building a broad portfolio of innovative young biotech companies to deliver important new therapies for patients and substantial value to our investors.”